ReviewFrontiers in immunology2026
Neuroinflammatory regulatory role of microglia in optic nerve injury: from pathological mechanisms to therapeutic targets.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- ZBP1 in Neuroinflammation and Neurodegeneration: Z-Nucleic-Acid Sensing, RHIM Signalling and Therapeutic Targeting.International journal of molecular sciences · 2026Review
- The Eye as a Window to Neurodegeneration: Oxidative Stress, Optic Nerve Vulnerability, and Retinal Biomarkers-A Scoping Review.Antioxidants (Basel, Switzerland) · 2026Review
- Metabolic Intervention with Dimethyl Malonate Impairs Phagocytic Clearance but Fails to Protect Neurons.bioRxiv : the preprint server for biology · 2026Article
- Dual immune armies in glaucoma: microglia and monocyte-derived macrophages.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optic nerve injury, encompassing conditions such as glaucoma, optic neuritis, and traumatic optic neuropathy, is a major cause of irreversible vision loss. Traditional broad-spectrum anti-inflammatory treatments have shown limited efficacy, highlighting the need for precision-based therapeutic approaches grounded in the underlying pathological mechanisms. As the primary immune cells of the central nervous system (CNS), microglia play a crucial role in regulating neuroinflammation following optic nerve injury. This review provides a comprehensive overview of the mechanisms governing microglial neuroinflammatory regulation, including early inflammatory signal recognition mediated by damage-associated molecular patterns (DAMPs), dynamic transcriptional networks regulating polarization between pro-inflammatory and pro-repair phenotypes, bidirectional modulation of phagocytic clearance by the complement system, and the complex multicellular interactions among microglia, astrocytes, and Müller cells. The concept of conditioning injury conditioning injury (intraocular inflammatory stimulation) has revealed the dual nature of neuroinflammatory responses: through temporal polarization shifts, microglia can both release neurotoxic mediators that worsen injury and secrete neurotrophic factors that promote axonal regeneration and myelin repair. This shift from traditional broad-spectrum anti-inflammatory strategies to precision functional modulation forms the basis for emerging therapeutic approaches, including PPARγ pathway activation, selective complement system targeting, and time-dependent modulation. We also assess the potential of advanced technologies, such as nanodelivery systems, single-cell analysis, and molecular imaging, in precision diagnosis and treatment. Finally, we critically examine the limitations of current research, including interspecies variability, model constraints, and clinical translation barriers, and discuss the translational potential of microglia-targeted therapies in protecting and restoring clinically meaningful visual function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.